Experts share here what they take away from CROI each year and why this meeting is so important in this space.

One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...

News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

As scientists gathered at the Conference for Retroviruses and Opportunistic Infections, or CROI, for meetings that run through Wednesday, they face an uncertain future. It was evident in who was ...

There were empty seats in San Francisco last week at an annual international science conference which has delivered some of ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...